Predictors of Remodeling in the CRT Era: Influence of Mitral Regurgitation, BNP, and Gender

Journal of Cardiac Failure

Volumn 12, Issue 3, 2006, Pages 182-188

  Cappola, Thomas P ^a   Harsch, Manya R ^b   Jessup, Mariell ^a   Abraham, William T ^c   Young, James B ^d   Petersen Stejskal, Susan ^b   Plappert, Ted ^a   St John Sutton, Martin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDTRONIC INC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

echocardiography; epidemiology; gender; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MULTIVARIATE ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEX DIFFERENCE;

AGED; CARDIAC PACING, ARTIFICIAL; CARDIOMEGALY; DISEASE PROGRESSION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDE, BRAIN; SEX FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33646027310     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2005.11.003     Document Type: Article

References (31)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
2. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., and Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 336 (1997) 1350-1355
3. de Simone G., Verdecchia P., Pede S., Gorini M., and Maggioni A.P. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension 40 (2002) 470-476
4. Ganau A., Devereux R.B., Roman M.J., de Simone G., Pickering T.G., Saba P.S., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
5. St John S.M., Pfeffer M.A., Plappert T., Rouleau J.L., Moye L.A., Dagenais G.R., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 89 (1994) 68-75
6. Wong M., Staszewsky L., Latini R., Barlera S., Glazer R., Aknay N., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 43 (2004) 2022-2027
7. Levy D., Larson M.G., Vasan R.S., Kannel W.B., and Ho K.K. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
8. Mosterd A., D'Agostino R.B., Silbershatz H., Sytkowski P.A., Kannel W.B., Grobbee D.E., et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 340 (1999) 1221-1227
9. St John S.M., Pfeffer M.A., Moye L., Plappert T., Rouleau J.L., Lamas G., et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 96 (1997) 3294-3299
10. Abraham W.T., Fisher W.G., Smith A.L., DeLurgio D.B., Leon A.R., Loh E., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
11. Young J.B., Abraham W.T., Smith A.L., Leon A.R., Lieberman R., Wilkoff B., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289 (2003) 2685-2694
12. Rector T.S., and Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 124 (1992) 1017-1025
13. St. John-Sutton M., Plappert T., Abraham W.T., Smith A.L., DeLurgio D.B., Leon A.R., et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107 (2003) 1985-1990
14. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
15. Carabello B.A., and Crawford Jr. F.A. Valvular heart disease. N Engl J Med 337 (1997) 32-41
16. Bellenger N.G., Burgess M.I., Ray S.G., Lahiri A., Coats A.J., Cleland J.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 21 (2000) 1387-1396
17. Ghali J.K., Krause-Steinrauf H.J., Adams K.F., Khan S.S., Rosenberg Y.D., Yancy C.W., et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 42 (2003) 2128-2134
18. Roger V.L., Weston S.A., Redfield M.M., Hellermann-Homan J.P., Killian J., Yawn B.P., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 (2004) 344-350
19. Carroll J.D., Carroll E.P., Feldman T., Ward D.M., Lang R.M., McGaughey D., et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 86 (1992) 1099-1107
20. Kostkiewicz M., Tracz W., Olszowska M., Podolec P., and Drop D. Left ventricular geometry and function in patients with aortic stenosis: gender differences. Int J Cardiol 71 (1999) 57-61
21. Bella J.N., Palmieri V., Wachtell K., Liu J.E., Gerdts E., Nieminen M.S., et al. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 18 (2004) 411-416
22. Gerdts E., Zabalgoitia M., Bjornstad H., Svendsen T.L., and Devereux R.B. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 8 (2001) 980-983
23. Crabbe D.L., Dipla K., Ambati S., Zafeiridis A., Gaughan J.P., Houser S.R., et al. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 41 (2003) 300-306
24. Douglas P.S., Katz S.E., Weinberg E.O., Chen M.H., Bishop S.P., and Lorell B.H. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 32 (1998) 1118-1125
25. Weinberg E.O., Thienelt C.D., Katz S.E., Bartunek J., Tajima M., Rohrbach S., et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 34 (1999) 264-273
26. Wu J.C., Nasseri B.A., Bloch K.D., Picard M.H., and Scherrer-Crosbie M. Influence of sex on ventricular remodeling after myocardial infarction in mice. J Am Soc Echocardiogr 16 (2003) 1158-1162
27. Weinberg E.O., Mirotsou M., Gannon J., Dzau V.J., Lee R.T., and Pratt R.E. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics 12 (2003) 113-127
28. Xin H.B., Senbonmatsu T., Cheng D.S., Wang Y.X., Copello J.A., Ji G.J., et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416 (2002) 334-338
29. Gao X.M., Agrotis A., Autelitano D.J., Percy E., Woodcock E.A., Jennings G.L., et al. Sex hormones and cardiomyopathic phenotype induced by cardiac beta 2-adrenergic receptor overexpression. Endocrinology 144 (2003) 4097-4105
30. Vasan R.S., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sundstrom J., et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43 (2004) 957-962
31. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109 (2004) 2850-2856